Phillip L Pearl1,2, Keith Hyland3, J Chiles3, Colleen L McGavin4, Yuezhou Yu4, Donald Taylor5. 1. Department of Neurology, Children's National Medical Center, George Washington University School of Medicine, Washington, DC, USA. ppearl@childrensnational.org. 2. Department of Neurology, Children's National Medical Center, 111 Michigan Ave, NW, Washington, DC, 20010, USA. ppearl@childrensnational.org. 3. Medical Neurogenetics, Atlanta, GA, USA. 4. Department of Neurology, Children's National Medical Center, George Washington University School of Medicine, Washington, DC, USA. 5. Child Neurology Associates, Richmond, VA, USA.
Abstract
OBJECTIVE: Autosomal-recessive pyridox(am)ine phosphate oxidase (PNPO) deficiency causes pyridoxal-5-phosphate (PLP)-dependent epilepsy. We describe partial PNPO deficiency with a transient response to pyridoxine (B6). METHODS: CSF neurotransmitter metabolites, PLP, and amino acids were analyzed while the patient was receiving pyridoxine. PNPO gene sequencing was performed by standard techniques. RESULTS: A full-term 3,220 g male with refractory neonatal seizures became seizure free for 6 weeks on pyridoxine (B6). Breakthrough seizures followed. These stopped upon the first dose of PLP although episodes occurred as a dose became due. An unidentified peak was detected on the chromatographic system used to measure CSF PLP. PNPO gene sequencing identified a homozygous mutation in a highly conserved area in exon 3: c.352G>A p.G118R, predicting substitution of arginine for glycine. At age 28 months the child has hypotonia and developmental delay, both mild in severity. CONCLUSIONS: Transient pyridoxine responsiveness may be seen in partial PNPO deficiency. A CSF metabolite peak, likely pyridoxine phosphate, is identifiable in patients with PNPO deficiency who are taking supplemental pyridoxine. Partial B6 responsiveness is an indication for possible PNPO deficiency and trial of PLP.
OBJECTIVE: Autosomal-recessive pyridox(am)ine phosphate oxidase (PNPO) deficiency causes pyridoxal-5-phosphate (PLP)-dependent epilepsy. We describe partial PNPO deficiency with a transient response to pyridoxine (B6). METHODS: CSF neurotransmitter metabolites, PLP, and amino acids were analyzed while the patient was receiving pyridoxine. PNPO gene sequencing was performed by standard techniques. RESULTS: A full-term 3,220 g male with refractory neonatal seizures became seizure free for 6 weeks on pyridoxine (B6). Breakthrough seizures followed. These stopped upon the first dose of PLP although episodes occurred as a dose became due. An unidentified peak was detected on the chromatographic system used to measure CSF PLP. PNPO gene sequencing identified a homozygous mutation in a highly conserved area in exon 3: c.352G>A p.G118R, predicting substitution of arginine for glycine. At age 28 months the child has hypotonia and developmental delay, both mild in severity. CONCLUSIONS: Transient pyridoxine responsiveness may be seen in partial PNPO deficiency. A CSF metabolite peak, likely pyridoxine phosphate, is identifiable in patients with PNPO deficiency who are taking supplemental pyridoxine. Partial B6 responsiveness is an indication for possible PNPO deficiency and trial of PLP.
Authors: Philippa B Mills; Eduard Struys; Cornelis Jakobs; Barbara Plecko; Peter Baxter; Matthias Baumgartner; Michèl A A P Willemsen; Heymut Omran; Uta Tacke; Birgit Uhlenberg; Bernhard Weschke; Peter T Clayton Journal: Nat Med Date: 2006-02-19 Impact factor: 53.440
Authors: Sylvia Stockler; Barbara Plecko; Sidney M Gospe; Marion Coulter-Mackie; Mary Connolly; Clara van Karnebeek; Saadet Mercimek-Mahmutoglu; Hans Hartmann; Gunter Scharer; Eduard Struijs; Ingrid Tein; Cornelis Jakobs; Peter Clayton; Johan L K Van Hove Journal: Mol Genet Metab Date: 2011-05-24 Impact factor: 4.797
Authors: Philippa B Mills; Robert A H Surtees; Michael P Champion; Clare E Beesley; Neil Dalton; Peter J Scambler; Simon J R Heales; Anthony Briddon; Irene Scheimberg; Georg F Hoffmann; Johannes Zschocke; Peter T Clayton Journal: Hum Mol Genet Date: 2005-03-16 Impact factor: 6.150
Authors: Bernhard Schmitt; Matthias Baumgartner; Philippa B Mills; Peter T Clayton; Cornelis Jakobs; Elmar Keller; Gabriele Wohlrab Journal: Dev Med Child Neurol Date: 2010-03-29 Impact factor: 5.449
Authors: Emma J Footitt; Peter T Clayton; Kevin Mills; Simon J Heales; Viruna Neergheen; Marcus Oppenheim; Philippa B Mills Journal: J Inherit Metab Dis Date: 2012-05-11 Impact factor: 4.982
Authors: Marta Molina Romero; Alberto Yoldi Chaure; Miguel Gañán Parra; Purificación Navas Bastida; José Luis Del Pico Sánchez; Ángel Vaquero Argüelles; Paloma de la Fuente Vaquero; Juan Pablo Ramírez López; José Antonio Castilla Alcalá Journal: J Assist Reprod Genet Date: 2022-01-29 Impact factor: 3.412
Authors: Alina Levtova; Stephane Camuzeaux; Anne-Marie Laberge; Pierre Allard; Catherine Brunel-Guitton; Paola Diadori; Elsa Rossignol; Keith Hyland; Peter T Clayton; Philippa B Mills; Grant A Mitchell Journal: JIMD Rep Date: 2015-03-12
Authors: Réjean M Guerriero; Archana A Patel; Brian Walsh; Fiona M Baumer; Ankoor S Shah; Jurriaan M Peters; Lance H Rodan; Pankaj B Agrawal; Phillip L Pearl; Masanori Takeoka Journal: Pediatr Neurol Date: 2017-06-03 Impact factor: 3.372
Authors: Philippa B Mills; Stephane S M Camuzeaux; Emma J Footitt; Kevin A Mills; Paul Gissen; Laura Fisher; Krishna B Das; Sophia M Varadkar; Sameer Zuberi; Robert McWilliam; Tommy Stödberg; Barbara Plecko; Matthias R Baumgartner; Oliver Maier; Sophie Calvert; Kate Riney; Nicole I Wolf; John H Livingston; Pronab Bala; Chantal F Morel; François Feillet; Francesco Raimondi; Ennio Del Giudice; W Kling Chong; Matthew Pitt; Peter T Clayton Journal: Brain Date: 2014-03-18 Impact factor: 13.501